価格表
在庫・価格 : 2025年02月18日 05時56分 現在
商品名 | 商品コード | メーカー | 包装 | 価格 | 在庫 | リスト |
---|---|---|---|---|---|---|
Osteoprotegerin, ELISA Kit (12×8tests) <OPG, ELISA Kit> データシート |
BI-20403 |
BMCバイオメディカ BIOMEDICA Medizinprodukte GmbH |
1 kit | ¥151,000 |
無 (未発注) |
追加 |
在庫・価格 : 2025年02月18日 05時56分 現在
使用文献
- No.: 1
-
文献情報:
Galeone A et al. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures. Eur J Cardiothorac Surg 2013 Aug;44(2):e141-
Galeone A et al
2013/01/01
-
備考:
-
参照:
- No.: 2
-
文献情報:
Liu JM et al. An independent positive relationship between the serum total osteocalcin level and fat-free mass in healthy premenopausal women. J. Clin. Endocrinol. Metab. 2013 May;98(5):2146-52
Liu JM et al
2013/01/01
-
備考:
-
参照:
- No.: 3
-
文献情報:
de Rooy DP et al. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann. Rheum. Dis. 2013 May;72(5):769-75
de Rooy DP et al
2013/01/01
-
備考:
-
参照:
- No.: 4
-
文献情報:
Brunetti G et al. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am. J. Physiol. Endocrinol. Metab. 2013 Mar;304(5):E546-54
Brunetti G et al
2013/01/01
-
備考:
-
参照:
- No.: 5
-
文献情報:
Szulc P et al. Serum myostatin levels are negatively associated with abdominal aortic calcification in older men: the STRAMBO study. Eur. J. Endocrinol. 2012 Dec;167(6):873-80
Szulc P et al
2012/01/01
-
備考:
-
参照:
- No.: 6
-
文献情報:
Kaneko K et al. Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts. J. Clin. Endocrinol. Metab. 2012 Oct;97(10):E1909-17
Kaneko K et al
2012/01/01
-
備考:
-
参照:
- No.: 7
-
文献情報:
Ardawi MS et al. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J. Clin. Endocrinol. Metab. 2012 Oct;97(10):3691-9
Ardawi MS et al
2012/01/01
-
備考:
-
参照:
- No.: 8
-
文献情報:
Spatz JM et al. Serum sclerostin increases in healthy adult men during bed rest. J. Clin. Endocrinol. Metab. 2012 Sep;97(9):E1736-40
Spatz JM et al
2012/01/01
-
備考:
-
参照:
- No.: 9
-
文献情報:
Varsavsky M et al. Serum osteoprotegerin and sex steroid levels in patients with prostate cancer. J. Androl. ;33(4):594-600
Varsavsky M et al
-
備考:
-
参照:
- No.: 10
-
文献情報:
Melchiorre D et al. RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology. J. Rheumatol. 2012 Aug;39(8):1678-86
Melchiorre D et al
2012/01/01
-
備考:
-
参照:
- No.: 11
-
文献情報:
Sakakeeny L et al. Plasma pyridoxal-5-phosphate is inversely associated with systemic markers of inflammation in a population of U.S. adults. J. Nutr. 2012 Jul;142(7):1280-5
Sakakeeny L et al
2012/01/01
-
備考:
-
参照:
- No.: 12
-
文献情報:
Svensson M et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol. Dial. Transplant. 2012 Jun;27(6):2571-5
Svensson M et al
2012/01/01
-
備考:
-
参照:
- No.: 13
-
文献情報:
Schoppet M et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J. Clin. Endocrinol. Metab. 2012 Apr;97(4):E575-83
Schoppet M et al
2012/01/01
-
備考:
-
参照:
- No.: 14
-
文献情報:
Makras P et al. Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis. J. Clin. Endocrinol. Metab. 2012 Apr;97(4):E618-21
Makras P et al
2012/01/01
-
備考:
-
参照:
- No.: 15
-
文献情報:
Engvall IL et al. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. Rheumatology (Oxfo
Engvall IL et al
2013/01/01
-
備考:
-
参照:
- No.: 16
-
文献情報:
Amrein K et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J. Clin. Endocrinol. Metab. 2012 Jan;97(1):148-54
Amrein K et al
2012/01/01
-
備考:
-
参照:
- No.: 17
-
文献情報:
Ng AC et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS. Blood 2011 Dec;118(25):6529-34
Ng AC et al
2011/01/01
-
備考:
-
参照:
- No.: 18
-
文献情報:
Stavroulopoulos A et al. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol. Dial. Transplant. 2011 Aug;26(8):2582-9
Stavroulopoulos A et al
2011/01/01
-
備考:
-
参照:
- No.: 19
-
文献情報:
Szulc P et al. Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. J. Clin. Endocrinol. Metab. 2011 Jul;96(7):2216-26
Szulc P et al
2011/01/01
-
備考:
-
参照:
- No.: 20
-
文献情報:
Pepene CE et al. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur. J. Endocrinol. 2011 Jan;164(1):61-8
Pepene CE et al
2011/01/01
-
備考:
-
参照:
- No.: 21
-
文献情報:
Park JS et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur. J. Endocrinol. 2011 Jan;164(1):69-74
Park JS et al
2011/01/01
-
備考:
-
参照:
- No.: 22
-
文献情報:
Rauner M et al. Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology 2011 Jan;152(1):103-12
Rauner M et al
2011/01/01
-
備考:
-
参照:
- No.: 23
-
文献情報:
Westenfeld R et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease. Nephrol. Dial. Transplant. 2011 Dec;26(12):4115-23
Westenfeld R et al
2011/01/01
-
備考:
-
参照:
- No.: 24
-
文献情報:
Lieb W et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler. Thromb. Vasc. Biol. 2010 Sep;30(9):1849-54
Lieb W et al
2010/01/01
-
備考:
-
参照:
- No.: 25
-
文献情報:
van Tuyl LH et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann. Rheum. Dis. 2010 Sep;69(9):1623-8
van Tuyl LH et al
2010/01/01
-
備考:
-
参照:
- No.: 26
-
文献情報:
Upadhyay A et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol. Dial. Transplant. 2011 Mar;26(3):920-6
Upadhyay A et al
2011/01/01
-
備考:
-
参照:
- No.: 27
-
文献情報:
Syversen SW et al. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann. Rheum. Dis. 2010 May;69(5):845-50
Syversen SW et al
2010/01/01
-
備考:
-
参照:
- No.: 28
-
文献情報:
Leung R et al. Diffuse osteosclerosis complicating hairy cell leukemia. J. Clin. Oncol. 2010 May;28(13):e203-4
Leung R et al
2010/01/01
-
備考:
-
参照:
- No.: 29
-
文献情報:
Mori K et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology ;61(1):86-91
Mori K et al
-
備考:
-
参照:
- No.: 30
-
文献情報:
Camozzi V et al. Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. Eur. J. Endocrinol. 2010 Jan;162(1):85-90
Camozzi V et al
2010/01/01
-
備考:
-
参照:
- No.: 31
-
文献情報:
Yang H et al. Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood 2009 Jul;114(2):425-36
Yang H et al
2009/01/01
-
備考:
-
参照:
- No.: 32
-
文献情報:
Gonz叩lez-Calvin JL et al. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J. Clin. Endocrinol. Metab. 2009 Dec;94(12):4844-50
Gonz叩lez-Calvin JL et al
2009/01/01
-
備考:
-
参照:
- No.: 33
-
文献情報:
Terpos E et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res. 2009 May;29(5):1651-7
Terpos E et al
2009/01/01
-
備考:
-
参照:
- No.: 34
-
文献情報:
Faienza MF et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J. Clin. Endocrinol. Metab. 2009 Jul;94(7):2269-
Faienza MF et al
2009/01/01
-
備考:
-
参照:
- No.: 35
-
文献情報:
Mencej-Bedrac S et al. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J. Mol. Endocrinol. 2009 Mar;42(3):239-47
Mencej-Bedrac S et al
2009/01/01
-
備考:
-
参照:
- No.: 36
-
文献情報:
Rauner M et al. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio. J. Rheumatol. 2009 Jan;36(1):120-6
Rauner M et al
2009/01/01
-
備考:
-
参照:
- No.: 37
-
文献情報:
Madar叩sz E et al. Osteoprotegerin levels in women with prior gestational diabetes mellitus. Diabetes Care 2009 Jan;32(1):e5
Madar叩sz E et al
2009/01/01
-
備考:
-
参照:
- No.: 38
-
文献情報:
Panizo S et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ. Res. 2009 May;104(9):1041-8
Panizo S et al
2009/01/01
-
備考:
-
参照:
- No.: 39
-
文献情報:
Mazzaferro S et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009 Mar;4(3):685-90
Mazzaferro S et al
2009/01/01
-
備考:
-
参照:
- No.: 40
-
文献情報:
Syversen SW et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J. Rheumatol. 2009 Feb;36(2):266-72
Syversen SW et al
2009/01/01
-
備考:
-
参照:
- No.: 41
-
文献情報:
Nybo M et al. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur. J. Endocrinol. 2008 Nov;159(5):603-8
Nybo M et al
2008/01/01
-
備考:
-
参照:
- No.: 42
-
文献情報:
Escobar-Morreale HF et al. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur. J. Endocrinol. 2008 Sep;159(3):225-32
Escobar-Morreale HF et al
2008/01/01
-
備考:
-
参照:
- No.: 43
-
文献情報:
Shea MK et al. Vitamin K, circulating cytokines, and bone mineral density in older men and women. Am. J. Clin. Nutr. 2008 Aug;88(2):356-63
Shea MK et al
2008/01/01
-
備考:
-
参照:
- No.: 44
-
文献情報:
Marini H et al. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J. Bone Miner. Res. 2008 May;23(5):715-20
Marini H et al
2008/01/01
-
備考:
-
参照:
- No.: 45
-
文献情報:
Shroff RC et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol. Dial. Transplant. 2008 Oct;23(10):3263-71
Shroff RC et al
2008/01/01
-
備考:
-
参照:
- No.: 46
-
文献情報:
Samelson EJ et al. Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J. Clin. Endocrinol. Metab. 2008 May;93(5):1789-95
Samelson EJ et al
2008/01/01
-
備考:
-
参照:
- No.: 47
-
文献情報:
Bakhireva LN et al. Does osteoprotegerin or receptor activator of nuclear factor-kappaB ligand mediate the association between bone and coronary artery calcification? J. Clin. Endocrinol. Metab. 2008 May;93(5):2009-12
Bakhireva LN et al
2008/01/01
-
備考:
-
参照:
- No.: 48
-
文献情報:
Styrkarsdottir U et al. Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med. 2008 May;358(22):2355-65
Styrkarsdottir U et al
2008/01/01
-
備考:
-
参照:
- No.: 49
-
文献情報:
Lorz C et al. The death ligand TRAIL in diabetic nephropathy. J. Am. Soc. Nephrol. 2008 May;19(5):904-14
Lorz C et al
2008/01/01
-
備考:
-
参照:
- No.: 50
-
文献情報:
Ominsky MS et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J. Bone Miner. Res. 2008 May;23(5):672-82
Ominsky MS et al
2008/01/01
-
備考:
-
参照:
- No.: 51
-
文献情報:
Kearns AE et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008 Apr;29(2):155-92
Kearns AE et al
2008/01/01
-
備考:
-
参照:
- No.: 52
-
文献情報:
Anastasilakis AD et al. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide. Eur. J. Endocrinol. 2008 Mar;158(3):411-5
Anastasilakis AD et al
2008/01/01
-
備考:
-
参照:
- No.: 53
-
文献情報:
Galusca B et al. Constitutional thinness: unusual human phenotype of low bone quality. J. Clin. Endocrinol. Metab. 2008 Jan;93(1):110-7
Galusca B et al
2008/01/01
-
備考:
-
参照:
- No.: 54
-
文献情報:
Anand DV et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J. Am. Coll. Cardiol. 2007 Dec;50(23):2218-25
Anand DV et al
2007/01/01
-
備考:
-
参照:
- No.: 55
-
文献情報:
Rodeo SA et al. The effect of osteoclastic activity on tendon-to-bone healing: an experimental study in rabbits. J Bone Joint Surg Am 2007 Oct;89(10):2250-9
Rodeo SA et al
2007/01/01
-
備考:
-
参照:
- No.: 56
-
文献情報:
Zheng Y et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res. 2007 Oct;67(19):9542-8
Zheng Y et al
2007/01/01
-
備考:
-
参照:
- No.: 57
-
文献情報:
Lamoureux F et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007 Aug;67(15):7308-18
Lamoureux F et al
2007/01/01
-
備考:
-
参照:
- No.: 58
-
文献情報:
Goranova-Marinova V et al. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 2007 Jul;92(7):1000-1
Goranova-Marinova V et al
2007/01/01
-
備考:
-
参照:
- No.: 59
-
文献情報:
Kiechl S et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007 Jul;116(4):385-91
Kiechl S et al
2007/01/01
-
備考:
-
参照:
- No.: 60
-
文献情報:
Joseph F et al. The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion. J. Clin. Endocrinol. Metab. 2007 Aug;92(8):3230-8
Joseph F et al
2007/01/01
-
備考:
-
参照:
- No.: 61
-
文献情報:
Samadfam R et al. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 2007 Jun;148(6):2778-87
Samadfam R et al
2007/01/01
-
備考:
-
参照:
- No.: 62
-
文献情報:
Stern A et al. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur. J. Endocrinol. 2007 May;156(5):555-62
Stern A et al
2007/01/01
-
備考:
-
参照:
- No.: 63
-
文献情報:
Lu Y et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res. 2007 Apr;67(8):3646-53
Lu Y et al
2007/01/01
-
備考:
-
参照:
- No.: 64
-
文献情報:
Helske S et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur. J. Heart Fail. 2007 Apr;9(4):357-63
Helske S et al
2007/01/01
-
備考:
-
参照:
- No.: 65
-
文献情報:
Hirbe AC et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 2007 Apr;109(8):3424-31
Hirbe AC et al
2007/01/01
-
備考:
-
参照:
- No.: 66
-
文献情報:
Lequerr辿 T et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 2007 Mar;46(3):446-53
Lequerr辿 T et al
2007/01/01
-
備考:
-
参照:
- No.: 67
-
文献情報:
Jefferson AL et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007 Mar;68(13):1032-8
Jefferson AL et al
2007/01/01
-
備考:
-
参照:
- No.: 68
-
文献情報:
Mancini L et al. Calcitonin and prednisolone display antagonistic actions on bone and have synergistic effects in experimental arthritis. Am. J. Pathol. 2007 Mar;170(3):1018-27
Mancini L et al
2007/01/01
-
備考:
-
参照:
- No.: 69
-
文献情報:
Secchiero P et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol. 2006 Dec;169(6):2236-44
Secchiero P et al
2006/01/01
-
備考:
-
参照:
- No.: 70
-
文献情報:
Clancy P et al. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler. Thromb. Vasc. Biol. 2006 Nov;26(11):2574-6
Clancy P et al
2006/01/01
-
備考:
-
参照:
- No.: 71
-
文献情報:
Gajewska J et al. Osteoprotegerin and C-telopeptide of type I collagen in Polish healthy children and adolescents. Adv Med Sci 2006;51:269-72
Gajewska J et al
2006/01/01
-
備考:
-
参照:
- No.: 72
-
文献情報:
Ziegler S et al. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005 Sep;182(1):175-80
Ziegler S et al
2005/01/01
-
備考:
-
参照:
- No.: 73
-
文献情報:
Ishii R et al. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006 Aug;47(2):194-9
Ishii R et al
2006/01/01
-
備考:
-
参照:
- No.: 74
-
文献情報:
Zhao HY et al. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporos Int 2005 Dec;16(12):1519-24
Zhao HY et al
2005/01/01
-
備考:
-
参照:
- No.: 75
-
文献情報:
Fiore CE et al. Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. Osteoporos Int 2005 Dec;16(12):2180-4
Fiore CE et al
2005/01/01
-
備考:
-
参照:
- No.: 76
-
文献情報:
Mezquita-Raya P et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005 Nov;16(11):1368-74
Mezquita-Raya P et al
2005/01/01
-
備考:
-
参照:
- No.: 77
-
文献情報:
Abrahamsen B et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 2005 Apr;36(4):727-35
Abrahamsen B et al
2005/01/01
-
備考:
-
参照:
- No.: 78
-
文献情報:
Harada M et al. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. Hum. Reprod. 2004 Oct;19(10):2188-91
Harada M et al
2004/01/01
-
備考:
-
参照:
- No.: 79
-
文献情報:
Colucci S et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004 Dec;104(12):3722-30
Colucci S et al
2004/01/01
-
備考:
-
参照:
- No.: 80
-
文献情報:
Skoumal M et al. Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. Ann. Rheum. Dis. 2004 Feb;63(2):216-7
Skoumal M et al
2004/01/01
-
備考:
-
参照:
- No.: 81
-
文献情報:
Liu JM et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif. Tissue Int. 2005 Jan;76(1):1-6
Liu JM et al
2005/01/01
-
備考:
-
参照:
- No.: 82
-
文献情報:
Schoppet M et al. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003 Mar;107(11):e76; author reply e76
Schoppet M et al
2003/01/01
-
備考:
-
参照:
- No.: 83
-
文献情報:
Eaton CL et al. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004 May;59(3):304-10
Eaton CL et al
2004/01/01
-
備考:
-
参照:
- No.: 84
-
文献情報:
Moschen AR et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005 Apr;54(4):479-87
Moschen AR et al
2005/01/01
-
備考:
-
参照:
- No.: 85
-
文献情報:
Melhus H. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004 Jun;291(22):2703; author reply 2703-4
Melhus H
2004/01/01
-
備考:
-
参照:
- No.: 86
-
文献情報:
Doi S et al. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. Ther Apher Dial 2004 Aug;8(4):335-9
Doi S et al
2004/01/01
-
備考:
-
参照:
- No.: 87
-
文献情報:
Hofbauer LC et al. Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathol. 2004 Jun;107(6):575-7, author reply 578
Hofbauer LC et al
2004/01/01
-
備考:
-
参照:
- No.: 88
-
文献情報:
Ambroszkiewicz J et al. A study of bone turnover markers in prepubertal children with phenylketonuria. Eur. J. Pediatr. 2004 Mar;163(3):177-8
Ambroszkiewicz J et al
2004/01/01
-
備考:
-
参照:
- No.: 89
-
文献情報:
Chan BY et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin. Chem. 2003 Dec;49(12):2083-5
Chan BY et al
2003/01/01
-
備考:
-
参照:
- No.: 90
-
文献情報:
Grzegorzewska AE et al. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. Rocz. Akad. Med. Bialymst. 2004;49:193-6
Grzegorzewska AE et al
2004/01/01
-
備考:
-
参照:
- No.: 91
-
文献情報:
Brubaker KD et al. Bone morphogenetic protein signaling in prostate cancer cell lines. J. Cell. Biochem. 2004 Jan;91(1):151-60
Brubaker KD et al
2004/01/01
-
備考:
-
参照:
- No.: 92
-
文献情報:
Buzi F et al. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin. Endocrinol. (Oxf) 2004 Jan;60(1):87-91
Buzi F et al
2004/01/01
-
備考:
-
参照:
- No.: 93
-
文献情報:
F叩brega E et al. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int. 2005 Apr;25(2):305-10
F叩brega E et al
2005/01/01
-
備考:
-
参照:
- No.: 94
-
文献情報:
Terpos E et al. Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma. Int. J. Hematol. 2003 Nov;78(4):344-8
Terpos E et al
2003/01/01
-
備考:
-
参照:
- No.: 95
-
文献情報:
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. Am. J. Hematol. 2003 Jan;72(1):34-7
Elhasid R et al
2003/01/01
-
備考:
-
参照:
- No.: 96
-
文献情報:
Alvarez L et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum. 2003 Mar;48(3):824-8
Alvarez L et al
2003/01/01
-
備考:
-
参照:
- No.: 97
-
文献情報:
Tsuji K et al. Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. J. Bone Miner. Metab. 2004;22(2):94-103
Tsuji K et al
2004/01/01
-
備考:
-
参照:
- No.: 98
-
文献情報:
Avbersek-Luznik I et al. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol. Dial. Transplant. 2005 Mar;20(3):566-70
Avbersek-Luznik I et al
2005/01/01
-
備考:
-
参照:
- No.: 99
-
文献情報:
Chan MH et al. Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. Pathology 2005 Feb;37(1):51-5
Chan MH et al
2005/01/01
-
備考:
-
参照:
- No.: 100
-
文献情報:
Corey E et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005 Mar;65(5):1710-8
Corey E et al
2005/01/01
-
備考:
-
参照:
- No.: 101
-
文献情報:
Hofbauer LC et al. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin. Endocrinol. (Oxf) 2004 Feb;60(2):214-9
Hofbauer LC et al
2004/01/01
-
備考:
-
参照:
- No.: 102
-
文献情報:
Kerschan-Schindl K et al. Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplant. 2004 Sep;34(6):491-6
Kerschan-Schindl K et al
2004/01/01
-
備考:
-
参照:
- No.: 103
-
文献情報:
von Tirpitz C et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003 Nov;15(11):1165-70
von Tirpitz C et al
2003/01/01
-
備考:
-
参照:
- No.: 104
-
文献情報:
Seminari E et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005 May;6(3):145-50
Seminari E et al
2005/01/01
-
備考:
-
参照:
- No.: 105
-
文献情報:
Pennisi P et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 2004 May;15(5):389-95
Pennisi P et al
2004/01/01
-
備考:
-
参照:
- No.: 106
-
文献情報:
Voskaridou E et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br. J. Haematol. 2003 Nov;123(4):730-7
Voskaridou E et al
2003/01/01
-
備考:
-
参照:
- No.: 107
-
文献情報:
Ueland T et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005 May;111(19):2461-8
Ueland T et al
2005/01/01
-
備考:
-
参照:
- No.: 108
-
文献情報:
Terpos E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004 Aug;18(8):1420-6
Terpos E et al
2004/01/01
-
備考:
-
参照:
- No.: 109
-
文献情報:
Salda単a L et al. Osteoblast response to thermally oxidized Ti6Al4V alloy. J Biomed Mater Res A 2005 Apr;73(1):97-107
Salda単a L et al
2005/01/01
-
備考:
-
参照:
- No.: 110
-
文献情報:
Moe SM et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005 Jun;67(6):2295-304
Moe SM et al
2005/01/01
-
備考:
-
参照:
- No.: 111
-
文献情報:
Pritzker LB et al. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell 2004 Jun;15(6):2834-41
Pritzker LB et al
2004/01/01
-
備考:
-
参照:
- No.: 112
-
文献情報:
Indridason OS et al. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005 Apr;16(4):417-23
Indridason OS et al
2005/01/01
-
備考:
-
参照:
- No.: 113
-
文献情報:
Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 2002 Jul;347(3):175-84
Whyte MP et al
2002/01/01
-
備考:
-
参照:
- No.: 114
-
文献情報:
Bekker PJ et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 2001 Feb;16(2):348-60
Bekker PJ et al
2001/01/01
-
備考:
-
参照:
- No.: 115
-
文献情報:
Kraj M et al. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Arch. Immunol. Ther. Exp. (Warsz.) ;53(5):454-64
Kraj M et al
-
備考:
-
参照:
- No.: 116
-
文献情報:
Fahrleitner A et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003 Jan;32(1):96-106
Fahrleitner A et al
2003/01/01
-
備考:
-
参照:
- No.: 117
-
文献情報:
Fahrleitner A et al. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. Wien. Klin. Wochenschr. 2002 Aug;114(15-16):717-24
Fahrleitner A et al
2002/01/01
-
備考:
-
参照:
- No.: 118
-
文献情報:
Hegedus D et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J. Bone Miner. Res. 2002 Nov;17(11):1961-7
Hegedus D et al
2002/01/01
-
備考:
-
参照:
- No.: 119
-
文献情報:
Kudlacek S et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003 Jun;32(6):681-6
Kudlacek S et al
2003/01/01
-
備考:
-
参照:
- No.: 120
-
文献情報:
Szalay F et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J. Hepatol. 2003 Apr;38(4):395-400
Szalay F et al
2003/01/01
-
備考:
-
参照:
- No.: 121
-
文献情報:
Terpos E et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003 Aug;102(3):1064-9
Terpos E et al
2003/01/01
-
備考:
-
参照:
- No.: 122
-
文献情報:
Anastasilakis AD et al. Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-head Clinical Trial. J. Clin. Endocrinol. Metab. 2013 Jun;
Anastasilakis AD et al
2013/01/01
-
備考:
-
参照:
- No.: 123
-
文献情報:
Dessein PH et al. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J. Rheumatol. 2014 Mar;41(3):429-36
Dessein PH et al
2014/01/01
-
備考:
-
参照:
- No.: 124
-
文献情報:
Kulcsar-Jakab E et al. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study. BMC Musculoskelet Disord 2015 Aug;16:227
Kulcsar-Jakab E et al
2015/01/01
-
備考:
-
参照:
- No.: 125
-
文献情報:
Ornstrup MJ et al. Adipose tissue, estradiol levels, and bone health in obese men with metabolic syndrome. Eur. J. Endocrinol. 2015 Feb;172(2):205-16
Ornstrup MJ et al
2015/01/01
-
備考:
-
参照:
- No.: 126
-
文献情報:
L坦pez-Robles C et al. Subclinical arteriosclerosis and osteoprotegerin levels in a population with systemic lupus erythematous in the south of Europe. Lupus 2016 Jun;25(7):781-2
L坦pez-Robles C et al
2016/01/01
-
備考:
-
参照:
- No.: 127
-
文献情報:
Jansen RB et al. Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study. J. Diabetes Complicat. 2018 02;32(2):164-170
Jansen RB et al
2018/01/01
-
備考:
-
参照:
- No.: 128
-
文献情報:
R淡ysland R et al. Osteoprotegerin concentrations in patients with suspected reversible myocardial ischemia: observations from the Akershus Cardiac Examination (ACE) 1 Study. Cytokine 2015 May;73(1):122-7
R淡ysland R et al
2015/01/01
-
備考:
-
参照:
- No.: 129
-
文献情報:
Telejko B et al. The association of bone turnover markers with pro- and anti-inflammatory adipokines in patients with gestational diabetes. Ann Agric Environ Med 2015;22(2):307-12
Telejko B et al
2015/01/01
-
備考:
-
参照:
- No.: 130
-
文献情報:
Moldovan D et al. Role of osteoprotegerin in vascular disorders of the end-stage renal disease patients. Biomarkers 2015 Mar;20(2):116-22
Moldovan D et al
2015/01/01
-
備考:
-
参照:
- No.: 131
-
文献情報:
Jasiewicz M et al. Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. Cytokine 2015 Dec;76(2):187-192
Jasiewicz M et al
2015/01/01
-
備考:
-
参照:
- No.: 132
-
文献情報:
Nemeth ZK et al. Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. Sci Rep 2015 Oct;5:14518
Nemeth ZK et al
2015/01/01
-
備考:
-
参照:
- No.: 133
-
文献情報:
Margonato A et al. Role of plaque calcification regulators osteoprotegerin and matrix Gla-proteins in stable angina and acute myocardial infarction. J Cardiovasc Med (Hagerstown) 2015 Mar;16(3):156-62
Margonato A et al
2015/01/01
-
備考:
-
参照:
- No.: 134
-
文献情報:
Alka巽 C et al. Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients. Turk J Med Sci 2015;45(6):1306-11
Alka巽 C et al
2015/01/01
-
備考:
-
参照:
- No.: 135
-
文献情報:
Faienza MF et al. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome. Bone 2015 Dec;81:228-236
Faienza MF et al
2015/01/01
-
備考:
-
参照:
- No.: 136
-
文献情報:
Rakic M et al. CD14 and TNFα single nucleotide polymorphisms are candidates for genetic biomarkers of peri-implantitis. Clin Oral Investig 2015 May;19(4):791-801
Rakic M et al
2015/01/01
-
備考:
-
参照:
- No.: 137
-
文献情報:
Ostrowska Z et al. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa. Endokrynol Pol 2015;66(4):313-21
Ostrowska Z et al
2015/01/01
-
備考:
-
参照:
- No.: 138
-
文献情報:
Gaudio A et al. Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease. Osteoporos Int 2015 Jun;26(6):1747-53
Gaudio A et al
2015/01/01
-
備考:
-
参照:
- No.: 139
-
文献情報:
Tohidi M et al. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. Bone 2012 Nov;51(5):876-81
Tohidi M et al
2012/01/01
-
備考:
-
参照:
- No.: 140
-
文献情報:
Oostra DR et al. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. Mol. Cell. Endocrinol. 2015 Feb;402:51-6
Oostra DR et al
2015/01/01
-
備考:
-
参照:
- No.: 141
-
文献情報:
Bonf叩 AC et al. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporos Int 2015 May;26(5):1563-71
Bonf叩 AC et al
2015/01/01
-
備考:
-
参照:
- No.: 142
-
文献情報:
Pereira RMR et al. Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH). Osteoporos Int 2016 11;27(11):3319-3329
Pereira RMR et al
2016/01/01
-
備考:
-
参照:
- No.: 143
-
文献情報:
Stuss M et al. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. Endokrynol Pol 2016;67(2):174-84
Stuss M et al
2016/01/01
-
備考:
-
参照:
- No.: 144
-
文献情報:
Caparbo VF et al. Monocytes from male patients with ankylosing spondylitis display decreased osteoclastogenesis and decreased RANKL/OPG ratio. Osteoporos Int 2018 Nov;29(11):2565-2573
Caparbo VF et al
2018/01/01
-
備考:
-
参照:
- No.: 145
-
文献情報:
Angelopoulos NG et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. J. Bone Miner. Metab. 2007;25(1):60-7
Angelopoulos NG et al
2007/01/01
-
備考:
-
参照:
- No.: 146
-
文献情報:
Uluçkan Ö et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med 2016 Mar;8(330):330ra37
Uluçkan Ö et al
2016/01/01
-
備考:
-
参照:
- No.: 147
-
文献情報:
Kushlinskii NE et al. Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. Bull. Exp. Biol. Med. 2017 Aug;163
Kushlinskii NE et al
2017/01/01
-
備考:
-
参照:
- No.: 148
-
文献情報:
Starup-Linde J et al. Differences in biochemical bone markers by diabetes type and the impact of glucose. Bone 2016 Feb;83:149-155
Starup-Linde J et al
2016/01/01
-
備考:
-
参照:
- No.: 149
-
文献情報:
Fonolla-Joya J et al. Daily Intake of Milk Enriched with n-3 Fatty Acids, Oleic Acid, and Calcium Improves Metabolic and Bone Biomarkers in Postmenopausal Women. J Am Coll Nutr 2016 08;35(6):529-536
Fonolla-Joya J et al
2016/01/01
-
備考:
-
参照:
- No.: 150
-
文献情報:
Feuerherm AJ et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand. J. Rheumatol. 2001;30(4):229-34
Feuerherm AJ et al
2001/01/01
-
備考:
-
参照:
- No.: 151
-
文献情報:
Ndip A et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011 Aug;60(8):2187-96
Ndip A et al
2011/01/01
-
備考:
-
参照:
- No.: 152
-
文献情報:
Assadi M et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PLoS ONE 2011;6(9):e24240
Assadi M et al
2011/01/01
-
備考:
-
参照:
- No.: 153
-
文献情報:
Josse AR et al. Diets higher in dairy foods and dietary protein support bone health during diet- and exercise-induced weight loss in overweight and obese premenopausal women. J. Clin. Endocrinol. Metab. 2012 Jan;97(1):251-60
Josse AR et al
2012/01/01
-
備考:
-
参照:
- No.: 154
-
文献情報:
Zupan J et al. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J. Biomed. Sci. 2012 Mar;19:28
Zupan J et al
2012/01/01
-
備考:
-
参照:
- No.: 155
-
文献情報:
V叩zquez MA et al. Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study. BMC Gastroenterol 2012 May;12:47
V叩zquez MA et al
2012/01/01
-
備考:
-
参照:
- No.: 156
-
文献情報:
Tenta R et al. Bone metabolism compensates for the delayed growth in small for gestational age neonates. Organogenesis ;9(1):55-9
Tenta R et al
-
備考:
-
参照:
- No.: 157
-
文献情報:
Botella S et al. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women. J. Clin. Endocrinol. Metab. 2013 Nov;98(11):E1740-8
Botella S et al
2013/01/01
-
備考:
-
参照:
- No.: 158
-
文献情報:
Saki F et al. Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. J. Bone Miner. Res. 2013 Jun;28(6):1501-8
Saki F et al
2013/01/01
-
備考:
-
参照:
- No.: 159
-
文献情報:
LaCroix AZ et al. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study. Bone 2013 Oct;56(2):474-81
LaCroix AZ et al
2013/01/01
-
備考:
-
参照:
- No.: 160
-
文献情報:
Revu S et al. Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. Arthritis Res. Ther. 2013;15(6):R205
Revu S et al
2013/01/01
-
備考:
-
参照:
- No.: 161
-
文献情報:
Faienza MF et al. Osteoclastogenic potential of peripheral blood mononuclear cells in cleidocranial dysplasia. Int J Med Sci 2014;11(4):356-64
Faienza MF et al
2014/01/01
-
備考:
-
参照:
- No.: 162
-
文献情報:
Negredo E et al. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. J. Antimicrob. Chemother. 2015 Jul;70(7):2104-7
Negredo E et al
2015/01/01
-
備考:
-
参照:
- No.: 163
-
文献情報:
Kastritis E et al. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. Blood Cancer J 2015 Jun;5:e319
Kastritis E et al
2015/01/01
-
備考:
-
参照:
- No.: 164
-
文献情報:
Kurz K et al. Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis. Dis. Markers 2015;2015:276969
Kurz K et al
2015/01/01
-
備考:
-
参照:
- No.: 165
-
文献情報:
Gifre L et al. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy. Osteoporos Int 2017 09;28(9):2707-2715
Gifre L et al
2017/01/01
-
備考:
-
参照:
- No.: 166
-
文献情報:
Ugay L et al. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease. Chin. Med. J. 2016 Jul;129(14):1696-703
Ugay L et al
2016/01/01
-
備考:
-
参照:
- No.: 167
-
文献情報:
Adami G et al. Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. Bone 2016 11;92:150-156
Adami G et al
2016/01/01
-
備考:
-
参照:
- No.: 168
-
文献情報:
Hauser B et al. Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcif. Tissue Int. 2017 10;101(4):375-383
Hauser B et al
2017/01/01
-
備考:
-
参照:
- No.: 169
-
文献情報:
Perp辿tuo IP et al. Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis. RMD Open 2017;3(1):e000365
Perp辿tuo IP et al
2017/01/01
-
備考:
-
参照:
- No.: 170
-
文献情報:
ナ嗟iwicka E et al. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing. PLoS ONE 2017;12(7):e0181259
ナ嗟iwicka E et al
2017/01/01
-
備考:
-
参照:
- No.: 171
-
文献情報:
Kiechl S et al. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget 2017 Jan;8(3):3811-3825
Kiechl S et al
2017/01/01
-
備考:
-
参照:
- No.: 172
-
文献情報:
Chrysis D et al. Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus. Pediatr Diabetes 2017 06;18(4):277-282
Chrysis D et al
2017/01/01
-
備考:
-
参照:
- No.: 173
-
文献情報:
Castroflorio T et al. Biochemical markers of bone metabolism during early orthodontic tooth movement with aligners. Angle Orthod 2017 Jan;87(1):74-81
Castroflorio T et al
2017/01/01
-
備考:
-
参照:
- No.: 174
-
文献情報:
Wu B et al. Craniometaphyseal dysplasia with obvious biochemical abnormality and rickets-like features. Clin. Chim. Acta 2016 May;456:122-127
Wu B et al
2016/01/01
-
備考:
-
参照:
- No.: 175
-
文献情報:
Lange U et al. Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients. Clin Transplant 2017 Nov;31(11)
Lange U et al
2017/01/01
-
備考:
-
参照:
- No.: 176
-
文献情報:
Anand DV et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J. Am. Coll. Cardiol. 2006 May;47(9):1850-7
Anand DV et al
2006/01/01
-
備考:
-
参照:
- No.: 177
-
文献情報:
Eleutherakis-Papaiakovou E et al. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2018 06;18(6):431-437
Eleutherakis-Papaiakovou E et al
2018/01/01
-
備考:
-
参照:
- No.: 178
-
文献情報:
Glasnović A et al. RANKL/RANK/OPG Axis Is Deregulated in the Cerebrospinal Fluid of Multiple Sclerosis Patients at Clinical Onset. Neuroimmunomodulation 2018;25(1):23-33
Glasnović A et al
2018/01/01
-
備考:
-
参照:
- No.: 179
-
文献情報:
Kardos Z et al. Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism? Clin. Rheumatol. 2018 May;37(5):1183-1188
Kardos Z et al
2018/01/01
-
備考:
-
参照:
- No.: 180
-
文献情報:
Hansen CS et al. Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes. Diabet. Med. 2018 11;35(11):1596-1604
Hansen CS et al
2018/01/01
-
備考:
-
参照:
- No.: 181
-
文献情報:
Bezerra MC et al. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology (Oxford) 2005 Dec;44(12):1503-6
Bezerra MC et al
2005/01/01
-
備考:
-
参照:
- No.: 182
-
文献情報:
Zojer N et al. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Anticancer Res. ;25(5):3607-12
Zojer N et al
-
備考:
-
参照:
- No.: 183
-
文献情報:
Sylvester FA et al. Are activated T cells regulators of bone metabolism in children with Crohn disease? J. Pediatr. 2006 Apr;148(4):461-6
Sylvester FA et al
2006/01/01
-
備考:
-
参照:
- No.: 184
-
文献情報:
Albalate M et al. Association between phosphate removal and markers of bone turnover in haemodialysis patients. Nephrol. Dial. Transplant. 2006 Jun;21(6):1626-32
Albalate M et al
2006/01/01
-
備考:
-
参照:
- No.: 185
-
文献情報:
Martini G et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Pagets disease of bone. Bone 2007 Feb;40(2):457-63
Martini G et al
2007/01/01
-
備考:
-
参照:
- No.: 186
-
文献情報:
Gohda T et al. Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease. Diabetes Res. Clin. Pract. 2018 Jul;141:62-68
Gohda T et al
2018/01/01
-
備考:
-
参照:
- No.: 187
-
文献情報:
Ornstrup MJ et al. Comparison of bone turnover markers in peripheral blood and bone marrow aspirate. Bone 2018 11;116:315-320
Ornstrup MJ et al
2018/01/01
-
備考:
-
参照:
- No.: 188
-
文献情報:
Bolamperti S et al. GH prevents adipogenic differentiation of mesenchymal stromal stem cells derived from human trabecular bone via canonical Wnt signaling. Bone 2018 07;112:136-144
Bolamperti S et al
2018/01/01
-
備考:
-
参照:
- No.: 189
-
文献情報:
Poornima IG et al. Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls. Lupus 2018 Jan;:961203317751060
Poornima IG et al
2018/01/01
-
備考:
-
参照:
- No.: 190
-
文献情報:
Yuksel S et al. Increased serum osteoprotegerin levels associated with decreased bone mineral density in familial Mediterranean fever. Tohoku J. Exp. Med. 2009 Apr;217(4):321-7
Yuksel S et al
2009/01/01
-
備考:
-
参照:
- No.: 191
-
文献情報:
Voorzanger-Rousselot N et al. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br. J. Cancer 2006 Aug;95(4):506-14
Voorzanger-Rousselot N et al
2006/01/01
-
備考:
-
参照:
- No.: 192
-
文献情報:
Terpos E et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br. J. Haematol. 2006 Dec;135(5):688-92
Terpos E et al
2006/01/01
-
備考:
-
参照:
- No.: 193
-
文献情報:
Terpos E et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoproteger
Terpos E et al
2005/01/01
-
備考:
-
参照:
- No.: 194
-
文献情報:
Rouster-Stevens KA et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum. 2007 Mar;56(3):977-83
Rouster-Stevens KA et al
2007/01/01
-
備考:
-
参照:
- No.: 195
-
文献情報:
Morabito N et al. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis. Bone 2007 Jun;40(6):1588-94
Morabito N et al
2007/01/01
-
備考:
-
参照:
- No.: 196
-
文献情報:
Monegal A et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. Liver Int. 2007 May;27(4):492-7
Monegal A et al
2007/01/01
-
備考:
-
参照:
- No.: 197
-
文献情報:
Mangiafico RA et al. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects. J. Intern. Med. 2007 Jun;261(6):587-96
Mangiafico RA et al
2007/01/01
-
備考:
-
参照:
- No.: 198
-
文献情報:
Whyte MP et al. Juvenile Pagets disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J. Bone Miner. Res. 2007 Jun;22(6):938
Whyte MP et al
2007/01/01
-
備考:
-
参照:
- No.: 199
-
文献情報:
Miheller P et al. Changes of OPG and RANKL concentrations in Crohns disease after infliximab therapy. Inflamm. Bowel Dis. 2007 Nov;13(11):1379-84
Miheller P et al
2007/01/01
-
備考:
-
参照:
- No.: 200
-
文献情報:
Suh KT et al. Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced bone mineral density in patients with adolescent idiopathic scoliosis. Eur Spine J 2007 Oct;16(10):1563-9
Suh KT et al
2007/01/01
-
備考:
-
参照:
- No.: 201
-
文献情報:
Pietschmann P et al. Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp. Gerontol. 2007 Nov;42(11):1099-108
Pietschmann P et al
2007/01/01
-
備考:
-
参照:
- No.: 202
-
文献情報:
Andersson MK et al. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients. Arthritis Res. Ther. 2007;9(1):R18
Andersson MK et al
2007/01/01
-
備考:
-
参照:
- No.: 203
-
文献情報:
Ertorer ME et al. Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: an open, prospective study. Curr Ther Res Clin Exp 2007 Jul;68(4):217-25
Ertorer ME et al
2007/01/01
-
備考:
-
参照:
- No.: 204
-
文献情報:
Kubota T et al. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res. The
Kubota T et al
2007/01/01
-
備考:
-
参照:
- No.: 205
-
文献情報:
Nakchbandi IA et al. The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2008 Mar;93(3):967-73
Nakchbandi IA et al
2008/01/01
-
備考:
-
参照:
- No.: 206
-
文献情報:
Zhao HY et al. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int 2008 Feb;19(2):221-6
Zhao HY et al
2008/01/01
-
備考:
-
参照:
- No.: 207
-
文献情報:
Santiago RA et al. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand. J. Rheumatol. ;37(1):40-7
Santiago RA et al
-
備考:
-
参照:
- No.: 208
-
文献情報:
Mangiafico RA et al. Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. Osteoporos Int 2008 Jan;19(1):49-56
Mangiafico RA et al
2008/01/01
-
備考:
-
参照:
- No.: 209
-
文献情報:
D'Amelio P et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J. Bone Miner. Res. 2008 Mar;23(3):373-9
D'Amelio P et al
2008/01/01
-
備考:
-
参照:
- No.: 210
-
文献情報:
Morishita M et al. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J. Rheumatol. 2008 Mar;35(3):407-13
Morishita M et al
2008/01/01
-
備考:
-
参照:
- No.: 211
-
文献情報:
Pilichou A et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin. Bioch
Pilichou A et al
2008/01/01
-
備考:
-
参照:
- No.: 212
-
文献情報:
Kwan Tat S et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin.
Kwan Tat S et al
-
備考:
-
参照:
- No.: 213
-
文献情報:
Kerschan-Schindl K et al. Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp. Clin. Endocrinol. Diabetes 2008 Aug;116(8):491-5
Kerschan-Schindl K et al
2008/01/01
-
備考:
-
参照:
- No.: 214
-
文献情報:
Giner M et al. Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts. Horm. Metab. Res. 2008 Dec;40(12):869-74
Giner M et al
2008/01/01
-
備考:
-
参照:
- No.: 215
-
文献情報:
Spelling P et al. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scand. J. Rheumatol. ;37(6):439-44
Spelling P et al
-
備考:
-
参照:
- No.: 216
-
文献情報:
Gua単abens N et al. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J. Bone Miner. Metab. 2009;27(3):347-54
Gua単abens N et al
2009/01/01
-
備考:
-
参照:
- No.: 217
-
文献情報:
Turk N et al. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohns disease. Eur J Gastroenterol Hepatol 2009 Feb;21(2):159-66
Turk N et al
2009/01/01
-
備考:
-
参照:
- No.: 218
-
文献情報:
Honsawek S et al. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. Pediatr. Surg. Int. 2009 Mar;25(3):261-7
Honsawek S et al
2009/01/01
-
備考:
-
参照:
- No.: 219
-
文献情報:
Karapanagiotou EM et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med. Oncol. 2010 Jun;27(2):332-8
Karapanagiotou EM et al
2010/01/01
-
備考:
-
参照:
- No.: 220
-
文献情報:
Rauchenzauner M et al. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev Med Child Neurol 2010 Mar;52(3):283-8
Rauchenzauner M et al
2010/01/01
-
備考:
-
参照:
- No.: 221
-
文献情報:
Kerschan-Schindl K et al. A 246-km continuous running race causes significant changes in bone metabolism. Bone 2009 Dec;45(6):1079-83
Kerschan-Schindl K et al
2009/01/01
-
備考:
-
参照:
- No.: 222
-
文献情報:
Rendina D et al. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcif. Tissue Int. 2009 Oct;85(4):293-300
Rendina D et al
2009/01/01
-
備考:
-
参照:
- No.: 223
-
文献情報:
Sauer AV et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 2009 Oct;114(15):3216-26
Sauer AV et al
2009/01/01
-
備考:
-
参照:
- No.: 224
-
文献情報:
Id Boufker H et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 2010 Jun;10:298
Id Boufker H et al
2010/01/01
-
備考:
-
参照:
- No.: 225
-
文献情報:
Wasilewska A et al. Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. Pediatr. Nephrol. 2010 Oct;25(10):2067-75
Wasilewska A et al
2010/01/01
-
備考:
-
参照:
- No.: 226
-
文献情報:
Carlson N et al. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis. Blood Purif. 2017;44(2):122-128
Carlson N et al
2017/01/01
-
備考:
-
参照:
- No.: 227
-
文献情報:
Bielesz B et al. Calcification Propensity of Serum is Independent of Excretory Renal Function. Sci Rep 2017 12;7(1):17941
Bielesz B et al
2017/01/01
-
備考:
-
参照:
- No.: 228
-
文献情報:
Terpos E et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin. Exp. Rheumatol. ;29(6):921-5
Terpos E et al
-
備考:
-
参照:
- No.: 229
-
文献情報:
Bergstr旦m I et al. Physical training increases osteoprotegerin in postmenopausal women. J. Bone Miner. Metab. 2012 Mar;30(2):202-7
Bergstr旦m I et al
2012/01/01
-
備考:
-
参照:
- No.: 230
-
文献情報:
Wu B et al. Atypical skeletal manifestations of rickets in a familial hypocalciuric hypercalcemia patient. Bone Res 2017;5:17001
Wu B et al
2017/01/01
-
備考:
-
参照:
- No.: 231
-
文献情報:
Rachner TD et al. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. Clin. Cancer Res. 2019 Feb;25(4):1369-1378
Rachner TD et al
2019/01/01
-
備考:
-
参照:
- No.: 232
-
文献情報:
Evenepoel P et al. Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. J. Bone Miner. Res. 2019 Feb;34(2):262-269
Evenepoel P et al
2019/01/01
-
備考:
-
参照:
- No.: 233
-
文献情報:
Zobel EH et al. Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. Diabetes Care 2017 03;40(3):e32-e33
Zobel EH et al
2017/01/01
-
備考:
-
参照:
- No.: 234
-
文献情報:
Szulc P et al. Severe abdominal aortic calcification in older men is negatively associated with DKK1 serum levels: the STRAMBO study. J. Clin. Endocrinol. Metab. 2014 Feb;99(2):617-24
Szulc P et al
2014/01/01
-
備考:
-
参照:
- No.: 235
-
文献情報:
Terpos E et al. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. Am. J. Hematol. 20
Terpos E et al
2019/01/01
-
備考:
-
参照:
- No.: 236
-
文献情報:
Turcotte AF et al. Effects of Biliopancreatic Diversion on Bone Turnover Markers and Association with Hormonal Factors in Patients with Severe Obesity. Obes Surg 2019 Mar;29(3):990-998
Turcotte AF et al
2019/01/01
-
備考:
-
参照:
- No.: 237
-
文献情報:
Evenepoel P et al. A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney Int. 2019 02;95(2):412-419
Evenepoel P et al
2019/01/01
-
備考:
-
参照:
- No.: 238
-
文献情報:
Frost M et al. Absence of an osteopetrosis phenotype in IKBKG (NEMO) mutation-positive women: A case-control study. Bone 2019 Apr;121:243-254
Frost M et al
2019/01/01
-
備考:
-
参照:
- No.: 239
-
文献情報:
Terpos E et al. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int. J. Cancer 2019 Jul;145(2):559-568
Terpos E et al
2019/01/01
-
備考:
-
参照:
- No.: 240
-
文献情報:
Hur S et al. Effect of Resistance Exercise on Serum Osteoprotegerin Levels and Insulin Resistance in Middle-Aged Women with Metabolic Syndrome. Med. Sci. Monit. 2018 Dec;24:9385-9391
Hur S et al
2018/01/01
-
備考:
-
参照:
- No.: 241
-
文献情報:
Evenepoel P et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int. 2019 Jun;95(6):1461-1470
Evenepoel P et al
2019/01/01
-
備考:
-
参照:
- No.: 242
-
文献情報:
Hruby A et al. Dietary Protein and Changes in Biomarkers of Inflammation and Oxidative Stress in the Framingham Heart Study Offspring Cohort. Curr Dev Nutr 2019 May;3(5):nzz019
Hruby A et al
2019/01/01
-
備考:
-
参照:
- No.: 243
-
文献情報:
Bernardes M et al. Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers. Biomed Res Int 2017;2017:6509754
Bernardes M et al
2017/01/01
-
備考:
-
参照:
- No.: 244
-
文献情報:
Biagioni MFG et al. Bariatric Roux-En-Y Gastric Bypass Surgery: Adipocyte Proteins Involved in Increased Bone Remodeling in Humans. Obes Surg 2017 Jul;27(7):1789-1796
Biagioni MFG et al
2017/01/01
-
備考:
-
参照:
- No.: 245
-
文献情報:
G坦mez-Vaquero C et al. Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. PLoS One 2016;11(12):e0166691
G坦mez-Vaquero C et al
2016/01/01
-
備考:
-
参照:
- No.: 246
-
文献情報:
Fekih O et al. Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes. Pediatr Diabetes 2017 May;18(3):230-236
Fekih O et al
2017/01/01
-
備考:
-
参照:
- No.: 247
-
文献情報:
Anagnostis P et al. The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study. Haemophilia 2018
Anagnostis P et al
2018/01/01
-
備考:
-
参照:
- No.: 248
-
文献情報:
Collado S et al. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function. BMC Nephrol 2017 Sep;18(1):290
Collado S et al
2017/01/01
-
備考:
-
参照:
- No.: 249
-
文献情報:
Sponder M et al. Endurance training significantly increases serum endocan but not osteoprotegerin levels: a prospective observational study. BMC Cardiovasc Disord 2017 Jan;17(1):13
Sponder M et al
2017/01/01
-
備考:
-
参照: